EGCG prevents pressure overload‑induced myocardial remodeling by downregulating overexpression of HDAC5 in mice

Int J Mol Med. 2022 Jan;49(1):11. doi: 10.3892/ijmm.2021.5066. Epub 2021 Nov 29.

Abstract

Myocardial remodeling is a complex pathological process and its mechanism is unclear. The present study investigated whether epigallocatechin gallate (EGCG) prevents myocardial remodeling by regulating histone acetylation and explored the mechanisms underlying this effect in the heart of a mouse model of transverse aortic constriction (TAC). A TAC mouse model was created by partial thoracic aortic banding (TAB). Subsequently, TAC mice were injected with EGCG at a dose of 50 mg/kg/day for 12 weeks. The hearts of mice were collected for analysis 4, 8 and 12 weeks after TAC. Histopathological changes in the heart were observed by hematoxylin and eosin, Masson trichrome and wheat germ agglutinin staining. Protein expression levels were investigated using western blotting. Cardiac function of mice was detected by echocardiography. The level of histone acetylated lysine 27 on histone H3 (H3K27ac) first increased and then decreased in the hearts of mice at 4, 8 and 12 weeks after TAC. The expression levels of two genes associated with pathological myocardial remodeling, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), also increased initially but then decreased. The expression levels of histone deacetylase 5 (HDAC5) gradually increased in the hearts of mice at 4, 8 and 12 weeks after TAC. Furthermore, EGCG increased acetylation of H3K27ac by inhibiting HDAC5 in the heart of TAC mice treated with EGCG for 12 weeks. EGCG normalized the transcriptional activity of heart nuclear transcription factor myocyte enhancer factor 2A in TAC mice treated for 12 weeks. The low expression levels of myocardial remodeling‑associated genes (ANP and BNP) were reversed by EGCG treatment for 12 weeks in TAC mice. In addition, EGCG reversed cardiac enlargement and improved cardiac function and survival in TAC mice when treated with EGCG for 12 weeks. Modification of the HDAC5‑mediated imbalance in histone H3K27ac served a key role in pathological myocardial remodeling. The present results show that EGCG prevented and delayed myocardial remodeling in TAC mice by inhibiting HDAC5.

Keywords: EGCG; HDAC; histone acetylation; mice; myocardial remodeling; treatment.

MeSH terms

  • Acetylation
  • Animals
  • Atrial Natriuretic Factor / metabolism
  • Atrial Remodeling / physiology
  • Catechin / analogs & derivatives*
  • Catechin / pharmacology
  • Constriction
  • Disease Models, Animal
  • Electrocardiography
  • Heart Failure / diagnostic imaging
  • Heart Failure / drug therapy*
  • Heart Failure / mortality
  • Heart Failure / prevention & control
  • Histone Deacetylases / metabolism*
  • Histones / metabolism
  • Lysine / metabolism
  • MEF2 Transcription Factors / genetics
  • MEF2 Transcription Factors / metabolism
  • Male
  • Natriuretic Peptide, Brain / metabolism
  • Survival Rate
  • Ventricular Remodeling

Substances

  • Histones
  • MEF2 Transcription Factors
  • Mef2a protein, mouse
  • Natriuretic Peptide, Brain
  • Atrial Natriuretic Factor
  • Catechin
  • epigallocatechin gallate
  • Hdac5 protein, mouse
  • Histone Deacetylases
  • Lysine

Grants and funding

The present study was supported by the National Natural Science Foundation of China (grant nos. 82060046 and 81560040).